Patents by Inventor Kathryn A. Phillips

Kathryn A. Phillips has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120329720
    Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.
    Type: Application
    Filed: June 29, 2012
    Publication date: December 27, 2012
    Applicant: YALE UNIVERSITY
    Inventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
  • Patent number: 8242240
    Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: August 14, 2012
    Assignee: Yale University
    Inventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
  • Publication number: 20110071092
    Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.
    Type: Application
    Filed: August 27, 2010
    Publication date: March 24, 2011
    Applicant: YALE UNIVERSITY
    Inventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
  • Patent number: 7812118
    Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: October 12, 2010
    Assignee: Yale University
    Inventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
  • Patent number: 7803774
    Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: September 28, 2010
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Mark A. Findeis, Kathryn Phillips, Gary L. Olsen, Christopher Self
  • Publication number: 20090286748
    Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.
    Type: Application
    Filed: April 9, 2009
    Publication date: November 19, 2009
    Applicant: Yale University
    Inventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
  • Patent number: 7534858
    Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: May 19, 2009
    Assignee: Yale University
    Inventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
  • Publication number: 20070248996
    Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Application
    Filed: November 14, 2006
    Publication date: October 25, 2007
    Applicant: Paraecis Pharmaceuticals, Inc.
    Inventors: Mark Findeis, Malcolm Gefter, Gary Musso, Ethan Signer, James Wakefield, Susan Molineaux, Joseph Chin, Jung-Ja Lee, Michael Kelley, Sonja Komar-Panicucci, Christopher Arico-Muendel, Kathryn Phillips, Neil Hayward
  • Patent number: 7175828
    Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3–5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: February 13, 2007
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Mark A. Findeis, Malcolm L. Gefter, Gary F. Musso, Ethan R. Signer, James Wakefield, Susan Molineaux, Joseph Chin, Jung-Ja Lee, Michael Kelley, Sonja Komar, Christopher C. Arico-Muendel, Kathryn Phillips, Neil J. Hayward
  • Publication number: 20060293244
    Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.
    Type: Application
    Filed: May 22, 2006
    Publication date: December 28, 2006
    Applicant: YALE UNIVERSITY
    Inventors: Michael May, Sankar Ghosh, Mark Findeis, Kathryn Phillips, Gerhard Hannig
  • Patent number: 7049395
    Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: May 23, 2006
    Assignee: Yale University
    Inventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
  • Publication number: 20060014696
    Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Application
    Filed: September 30, 2003
    Publication date: January 19, 2006
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Mark Findeis, Malcolm Gefter, Gary Musso, Ethan Signer, James Wakefield, Susan Molineaux, Joseph Chin, Jung-Ja Lee, Michael Kelley, Sonja Komar-Panicucci, Christopher Arico-Muendel, Kathryn Phillips, Neil Hayward
  • Publication number: 20050137128
    Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Application
    Filed: November 15, 2004
    Publication date: June 23, 2005
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Mark Findeis, Kathryn Phillips, Gary Olsen, Christopher Self
  • Patent number: 6831066
    Abstract: Compounds that modulate natural &bgr; amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a &bgr; amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a &bgr; amyloid peptide, preferably a retro-inverso isomer of A&bgr;17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: December 14, 2004
    Assignee: Praecis Pharmaceuticals Incorporated
    Inventors: Mark A. Findeis, Kathryn Phillips
  • Patent number: 6689752
    Abstract: Compounds that modulate natural &bgr; amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a &bgr; amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a &bgr; amyloid peptide, preferably a retro-inverso isomer of A&bgr;17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: February 10, 2004
    Assignee: Praecis Pharmaceuticals, Incorporated
    Inventors: Mark A. Findeis, Malcolm L. Gefter, Gary Musso, Ethan R. Signer, James Wakefield, Susan Molineaux, Joseph Chin, Jung-Ja Lee, Michael Kelley, Sonja Komar-Panicucci, Christopher C. Arico-Muendel, Kathryn Phillips, Neil J. Hayward
  • Publication number: 20030236197
    Abstract: Compounds that modulate natural &bgr; amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a &bgr; amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a &bgr; amyloid peptide, preferably a retro-inverso isomer of A&bgr;17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Application
    Filed: March 24, 2003
    Publication date: December 25, 2003
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Mark A. Findeis, Kathryn Phillips, Gary L. Olson, Christopher Self
  • Patent number: 6610658
    Abstract: Compounds that modulate natural &bgr; amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a &bgr; amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a &bgr; amyloid peptide, preferably a retro-inverso isomer of A&bgr;17-21. In certain embodiments, the peptide is modified at the: amino-terminus, carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: August 26, 2003
    Assignee: Praecis Pharmaceuticals Inc.
    Inventors: Mark A. Findeis, Kathryn Phillips, Gary L. Olson, Christopher Self
  • Publication number: 20030054999
    Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-&kgr;B-dependent target gene expression in a cell.
    Type: Application
    Filed: May 2, 2001
    Publication date: March 20, 2003
    Inventors: Michael J. May, Sankar Ghosh, Mark A. Findeis, Kathryn Phillips, Gerhard Hannig
  • Publication number: 20020103134
    Abstract: Compounds that modulate natural &bgr; amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a &bgr; amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a &bgr; amyloid peptide, preferably a retro-inverso isomer of A&bgr;17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Application
    Filed: June 29, 2001
    Publication date: August 1, 2002
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Mark A. Findeis, Malcolm L. Gefter, Gary Musso, Ethan R. Signer, James Wakefield, Susan Molineaux, Joseph Chin, Jung-Ja Lee, Michael Kelley, Sonja Komar-Panicucci, Christopher C. Arico-Muendel, Kathryn Phillips, Neil J. Hayward
  • Patent number: 6303567
    Abstract: Compounds that modulate natural &bgr; amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a &bgr; amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a &bgr; amyloid peptide, preferably a retro-inverso isomer of A&bgr;17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group.
    Type: Grant
    Filed: August 27, 1996
    Date of Patent: October 16, 2001
    Assignee: Praecis Pharmaceuticals, Inc .
    Inventors: Mark A. Findeis, Malcolm L. Gefter, Gary Musso, Ethan R. Signer, James Wakefield, Susan Molineaux, Joseph Chin, Jung-Ja Lee, Michael Kelley, Sonja Komar-Panicucci, Christopher C. Arico-Muendel, Kathryn Phillips, Neil J. Hayward